- Details
- Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...
|
- Details
- Alicia Morgans sits down with Neal Shore to discuss the ENACT trial, which investigates the use of enzalutamide in patients starting on active surveillance for prostate cancer. Dr. Shore explains that the trial aims to address the underutilization of active surveillance and explores whether enzalutamide can prevent upstaging of histopathology and reduce positive biopsies. The study, which was not...
|
- Details
- Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...
|
- Details
- Alicia Morgans speaks with Elena Castro and Colin Pritchard about the evolving role of molecular testing in treating men with prostate cancer. The discussion centers on the challenges and opportunities presented by recent data, particularly concerning combination therapies like Abiraterone and Olaparib. Dr. Pritchard emphasizes the importance of biomarkers in targeted therapies, while also acknowl...
|
- Details
- Brittany Szymaniak sheds light on the critical role of germline genetic testing in prostate cancer. Dr. Szymaniak emphasizes that genetic testing is not just for metastatic cases but also for high-risk, very high-risk, and even localized disease. Patients with Ashkenazi Jewish ancestry and those with a family history of various cancers, including male breast cancer, should also be considered for t...
|
- Details
- Alicia Morgans and Brittany Szymaniak address the intricacies of germline genetic testing in prostate cancer. They delve into the current NCCN and AUA guidelines, noting challenges in aligning these with practical implementation. Both experts highlight the lag in prostate cancer genetic testing compared to other cancers like breast and ovarian. They explore alternative models for pre-test and post...
|
- Details
- Alicia Morgans and Brenda Martone delve into the critical role of germline and somatic genetic testing in managing metastatic prostate cancer. Dr. Martone emphasizes the NCCN guidelines, which recommend offering both types of testing to patients with high-risk or metastatic disease. The conversation highlights the importance of family history and the broader implications of germline mutations, not...
|
- Details
- In this conversation, Fred Saad and Alicia Morgans discuss the critical role of bone health in treating patients with metastatic castration-resistant prostate cancer (mCRPC), particularly when using radium. Dr. Saad highlights that while newer cancer treatments like enzalutamide and abiraterone have been effective, they shouldn't overshadow the importance of bone health. He points to the PEACE III...
|
- Details
- Piet Ost discusses the treatment nuances and challenges surrounding biochemical recurrence in prostate cancer, specifically salvage radiation and androgen deprivation therapy (ADT). Dr. Ost highlights ongoing debates about when to add ADT and its duration, pointing to varying study outcomes. He also emphasizes the importance of discussing the pros and cons of ADT with patients due to its potential...
|
- Details
- Alicia Morgans sits down with Brandon Mahal to explore the complexities of using salvage systemic therapy alongside salvage radiation therapy for post-prostatectomy patients. Dr. Mahal outlines the current conundrum: whether to administer Androgen Deprivation Therapy (ADT) and for how long, especially for men with high PSAs post-surgery. He references multiple randomized trials that offer conflict...
|
